NGLFINE vs VENUSREM: Stock Comparison

NGL Fine-Chem Limited vs Venus Remedies Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Venus Remedies Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows a higher ROE, faster revenue growth and a higher ROCE, while Venus Remedies Limited shows a lower P/E, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of NGL Fine-Chem Limited and Venus Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NGLFINE is more favourable on 7 of 13 scored metrics and VENUSREM on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
VENUSREM is the larger company
₹2,270 Cr vs ₹2,015 Cr
P/E Ratio
VENUSREM has a lower P/E
20.57x vs 41.23x
P/B Ratio
VENUSREM has a lower P/B
3.6x vs 6.03x
EPS
NGLFINE has higher earnings per share
₹78.04 vs ₹76.93
Dividend Yield
VENUSREM has a higher dividend yield
0.56% vs 0.05%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 33%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs 126.4%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs 21.4%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNGLFINEVENUSREM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNGLFINEVENUSREM
Live Price₹3,260₹1,797.5
Day Change0.7%4.8%
Volume5,5952.46 L
52-Week High₹3,329₹1,800.8
52-Week Low₹1,175.5₹424
Distance from 52W High-2.07%-0.18%

Valuation

MetricNGLFINEVENUSREM
Market Cap₹2,015 Cr₹2,270 Cr
P/E Ratio41.23x20.57x
P/B Ratio6.03x3.6x
EPS₹78.04₹76.93
Book Value₹532.95₹444.63
Dividend Yield0.05%0.56%

Growth

MetricNGLFINEVENUSREM
Revenue Growth (TTM YoY)57.2%33%
EPS Growth (TTM YoY)1,539.8%126.4%
Qtr Sales Growth57.1%21.4%
Qtr Profit Growth2,398%687%

Profitability & Leverage

MetricNGLFINEVENUSREM
ROE15.7%15.48%
ROCE17%11.1%
Net Margin9.59%13.35%
Operating Margin14.5%17.44%
Debt to Equity0.33x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricNGLFINEVENUSREM
Promoter Holding72.74%41.76%
FII Holding0.03% 0.03 pp2.92% 0.12 pp
DII Holding0%0.89% 0.31 pp
Public Holding27.24% 0.02 pp54.43% 0.19 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL Fine-Chem Limited and Venus Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.